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Abstract
Objectives: Glutathionyl haemoglobin (GS-Hb) belonging to the class of glutathionylated proteins has been investigated as a possible marker
of oxidative stress in different chronic diseases. The purpose of this study was to examine whether glutathionyl haemoglobin can serve as an
oxidative stress marker in non-diabetic chronic renal failure patients on different renal replacement therapies (RRT) through its quantitation, and
characterization of the specific binding site of glutathione in haemoglobin molecule by mass spectrometric analysis.
Design and methods: The study group consisted of non-diabetic chronic renal failure patients on renal replacement therapy (RRT):
hemodialysis (HD), continuous ambulatory peritoneal dialysis (CAPD) and renal allograft transplant (Txp) patients. Haemoglobin samples of
these subjects were analyzed by liquid chromatography electrospray ionization mass spectrometry for GS-Hb quantitation. Characterization of GS-
Hb was done by tandem mass spectrometry. Levels of erythrocyte glutathione (GSH) and lipid peroxidation (as thiobarbituric acid reacting
substances) were measured spectrophotometrically, while glycated haemoglobin (HbA1c) was measured by HPLC.
Results: GS-Hb levels were markedly elevated in the dialysis group and marginally in the transplant group as compared to the controls. GS-Hb
levels correlated positively with lipid peroxidation and negatively with the erythrocyte glutathione levels in RRT groups indicating enhanced
oxidative stress. De novo sequencing of the chymotryptic fragment of GS-Hb established that glutathione is attached to Cys-93 of the beta globin
chain. Mass spectrometric quantitation of total glycated haemoglobin showed good agreement with HbA1c estimation by conventional HPLC
method.
Conclusions: Glutathionyl haemoglobin can serve as a clinical marker of oxidative stress in chronic debilitating therapies like RRT. Mass
spectrometry provides a reliable analytical tool for quantitation and residue level characterization of different post-translational modifications of
haemoglobin.
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failure is accompanied by very complex long-term manifesta-
tions such as accelerated aging, atherosclerosis, heart disease,
polyneuropathies and amyloidosis [1–3], which may be related
to the hyper-production of free radicals.
End-stage renal disease (ESRD) patients on renal replace-
ment therapy (RRT–dialysis/transplantation) are subjected to
enhanced oxidative stress as a result of reduced anti-oxidant
systems (vitamin C and selenium deficiency, reduced intracel-
lular levels of vitamin E, reduced activity of the glutathione. Published by Elsevier Inc. All rights reserved.
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(advanced age, high frequency of diabetes, chronic inflamma-
tory state, uremic syndrome, bio-incompatibility of dialysis
membranes and solutions) [4]. There is growing evidence, from
experimental and clinical studies, that oxidative stress may be
implicated in the pathogenesis of atherosclerosis and other
complications of ESRD [5]. This hypothesis is based on studies
that have conclusively demonstrated an increased oxidative
burden in uremic patients, before and particularly after renal
replacement therapies, as evidenced by increased or decreased
concentrations of multiple enzymatic/non-enzymatic biomar-
kers of oxidative stress [6–8].
Glutathione, in its reduced form (GSH), is an important
intracellular antioxidant compound. It prevents oxidation of
essential protein thiol groups induced by oxidative stress by
scavenging free radicals and detoxifying electrophiles [9].
Glutathione deficiency contributes to oxidative stress, which
plays a key role in aging and pathogenesis of many diseases [10].
GSH is oxidized to its dimeric form GSSG in response to an
oxidative perturbation. However, GSSG is rapidly reduced by
the action of glutathione reductase. If GSSG accumulates within
the cell, it can form protein–glutathione adducts via reversible
thiol exchange reactions referred to as S-glutathionylation of
protein [11,12]. Protein S-glutathionylation has been implicated
in the buffering of oxidative stress, stabilization of extracellular
proteins, protection of proteins against irreversible oxidation of
critical cysteine residues, and regulation of enzyme activity.
Protein S-glutathionylation may be induced by changes in the
intracellular redox potential as well as by the formation of ROS
[13,14]. Glutathionylated proteins (GSSPs) are more stable than
GSSG and less prone to enzymatic reduction by glutathione
reductase [15]. Thus, in addition to the ratio of GSH to GSSG,
the content of glutathionylated proteins (GSSPs) can serve as
indicators of oxidative stress. Within the RBCs, GSSG is found
to react with haemoglobin forming glutathionyl haemoglobin
(GS-Hb), which may serve as a useful clinical marker of
oxidative stress.
In recent years, a number of non-enzymatic post-translation-
ally modified proteins like haemoglobin adducts have been
investigated in quest of new markers for disease, for diagnostic
and/or prognostic purposes. A classic example is glycated
haemoglobin (HbA1c), which is used as an indicator of time
averaged glucose concentration in diabetic patients (6–8weeks).
Regular monitoring of glycated haemoglobin in diabetics is
recommended to prevent long-term diabetic complications.
Recently GS-Hb, another non-enzymatic post-translational
modification, has been recognized as a probable marker in
relation to oxidative stress in certain chronic diseases. Sig-
nificant increase in glutathionyl Hb concentration, compared to
its low value in healthy individuals has been found in diabetes
mellitus, hyperlipidemia, Friedreich ataxia, chronic renal fail-
ure–conditions where oxidative stress has been implicated [16–
19]. Characterization of glutathionyl haemoglobin at the residue
level could be important to assess the functional alteration as
possible adaptive mechanism in response to oxidative stress.
In this study, we have evaluated the degree of oxidative
stress by quantitation of GS-Hb in different RRT groups usingliquid chromatography–electrospray ionization mass spectro-
metry (LC/ESI-MS) in conjunction with other traditional
markers of oxidative stress. The site of glutathionylation has
been established using tandem mass spectrometry. The degree
of haemoglobin glycation measured by mass spectrometry is in
good agreement with established methodology.
Materials and methods
Patients
The study group consisted of patients in the age group of 30
to 68 years, who were recruited after obtaining written consent.
The study was approved by the hospital (Manipal Hospital,
Bangalore) ethics committee. Hemodialysis (HD) group con-
sisted of 15 patients (male=8, female=7) undergoing regular
dialysis of 12 h/week with 4 h in duration, using bicarbonate
dialysate and polysulfone membrane dialyzer. The peritoneal
dialysis (CAPD) group consisted of 12 continuous ambulatory
peritoneal dialysis patients (male=5, female=7) under dialysis
regimen for at least 6 months with a minimum of three
exchanges per day with dextrose dialysate (2% to 4.5%). The
transplant (Txp) group consisted of 15 stable renal allograft
patients (male=9, female=6) with minimum 1 year post
transplant period. Exclusion criteria were patients with diabetes,
intercurrent infections, chronic inflammatory conditions and
smokers. Control group consisted of 15 non-diabetic subjects
(male=8, female=7) with no history of renal failure or other
organ diseases.
Biochemical and clinical parameters
Fasting serum samples (blood collected in plain tubes without
anticoagulant) was used for routine biochemical analysis on an
automated chemistry analyzer (Dade Behring, USA) employing
standard methodology using the kits supplied by the manufac-
turer. HbA1cwas estimated by high-performance liquid chroma-
tography (HPLC) using an automated Variant HPLC system
(Bio-Rad, USA).
Glutathione estimation
Reduced erythrocyte glutathione (GSH) was estimated by the
modified method of Beutler et al. [20] with minor modifications
and GSH concentration was expressed in μmol/L whole blood.
Lipid peroxidation
Erythrocyte lipid peroxidation was measured as thiobarbi-
turic acid reacting substances (TBARS) by the method of Jain et
al. [21]. Molar extinction coefficient of 1.56×105 M−1 cm−1 of
1,1′,3,3′-tetramethoxypropane (MDA) was used to calculate the
TBARS concentration and expressed in nmol/g Hb.
Sample preparation
Venous blood anticoagulated with EDTA was the sample of
choice. Plasma and buffy coat were aspirated off after
centrifugation at 805×g for 10 min. The packed cells were
washed with 0.9% NaCl thrice before lysis with eight volumes
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at 12,880×g for 10 min to remove the erythrocyte membranes.
The clear supernatant was diluted 100 times with distilled water
prior to mass spectrometric analysis.
Quantitation of glutathionyl haemoglobin
Electrospray Ionization mass spectra were acquired in
positive ion mode using a single quadrupole mass spectrometer
(Hewlett Packard HP 1100 MSD series). 12 μL of sample was
injected through a C18 reverse phase analytical column
(Zorbax, 4.6 mm×150 mm, 5 μm), kept at ambient temperature
(25 °C). Hb was eluted using a linear gradient of acetonitrile
from 20% to 90% in 35 min with distilled water and acetonitrile
containing 0.1% acetic acid as the mobile phase. The flow rate
was maintained at 0.2 mL/min. Retention time for alpha and
beta chains of haemoglobin were 20.2 min and 20.9 min,
respectively. Data acquisition was set to full scan mode and the
spectra were acquired over the mass range 200–3000 m/z with a
scan time of 2.12 cycles/s. Mass scale calibration was done
using ES tuning mix supplied by the manufacturer. Deconvolu-
tion of the multiply charged species was performed using the
Chemstation software.
Since charge distribution of molecular ions of globin chains
and their adducts are identical in mass spectra, it can be
approximated that signal intensities can be correlated with their
abundance. The most intense signals for molecular ions cor-
responding to α and β subunits and their corresponding adducts
were distributed predominantly in the range of 17 to 21
protonated species. GS-Hb and Gly-Hb were quantitated from
the signal intensities of their respective molecular ions according
to the following equation [22]:
GS−Hbh % ¼ GS−Hbh  100hþ GS−Hbh þ Gly−Hbhð Þ
Gly−Hbh% ¼ Gly−Hbh  100hþ GS−Hbh þ Gly−Hbhð Þ
Gly−Hba % ¼ Gly−Hba  100aþ Gly−Hbað Þ
Characterization of glutathionyl haemoglobin
GS-Hb was prepared, in vitro, by incubating human
haemoglobin (3.5 g/dL) obtained from the RBC lysates, with
a large excess of GSSG (67 mmol/L) in 0.5 mol/L NH4HCO3
buffer (pH 8.0) for 12 h at 37 °C.
Enzyme digestion of GS-Hb was performed using chymo-
trypsin. 5 μL of GS-Hb sample was diluted with 40 μL of
0.05 mol/L NH4HCO3 buffer (pH 8.0). 5 μL of enzyme stock
solution (0.5 mg/mL) was added and kept for 12 h of incubation
at 37 °C.MS analysis
Samples were analyzed using an Ultraflex MALDI-TOF/
TOF mass spectrometer (Bruker Daltonics, Germany) in the
reflectron mode using a 90-ns time delay, and a 25-kV
accelerating voltage in the positive ion mode. The system
utilizes a 50 Hz pulsed nitrogen laser, emitting at 337 nm.
α-Cyano-4-hydroxy cinnamic acid was used as a matrix.
Tandem mass (MS/MS) spectra were acquired by selecting
the precursor mass with a 10-Da window, and fragments were
generated in post source decay mode (PSD). A single acquisition
run was the sum of at least 50 series with 600 total added shots to
generate the MS/MS spectra. Mass spectra were analyzed using
Flex-analysis software, provided by the manufacturer.
Statistical analysis
Quantitative data are expressed as mean±SD. Group
comparison was done by Student's t-test and pb0.05 was
considered significant. Univariate regression analysis was done
using online statistical analysis programme.
Results
Table 1 shows clinical parameters of patient groups
compared to the control group. Decrease in GSH was more
pronounced in the dialysis group with no significant changes in
the transplant group. Similarly, an increase in the lipid
peroxidation of erythrocytes as indicated by increased
TBARS levels was significantly higher in the dialysis group
compared to the transplant group. Decreased GSH, observed in
the dialysis group, correlated negatively with the erythrocyte
TBARS (r=−0.63; pb0.001). A positive correlation was
observed between the duration of RRT and GS-Hb (r=0.744,
p=0.001) in the dialysis group.
Fig. 1 shows the ESI mass spectrum of haemoglobin from a
control subject. Panel A and B shows mass spectra of alpha and
beta globin chains with their adducts, respectively. Deconvolu-
tion of the mass spectral signals corresponding to different
charged states yielded almost precise masses (±2 Da) of Hbα,
Hbβ and their adducts. The alpha and beta set consisted of the
following masses: α (15,125 Da; Mcalculated, 15,126 Da),
glycated α (15,287 Da; Mcalculated 15,288 Da), β (15,866 Da;
Mcalculated, 15,867 Da), glycated β (16,028 Da; Mcalculated,
16,029 Da) and glutathionylated β (16,171 Da; Mcalculated,
16,172 Da). Fig. 2 shows the ESI-MS of alpha globin chain and
its adduct for RRT groups. Panels A, B, and C correspond to
transplant, CAPD and HD, respectively, with their deconvoluted
mass spectra shown as insets. Fig. 3 shows the ESI-MS of beta
globin chain and its adducts for the patient category in the same
order. We observed augmented intensities for glutathionyl
haemoglobin in HD and CAPD compared to the transplant
group and relatively higher peak intensities for glycated adducts
in both the globin chains in CAPD group compared to the other
two groups.
In all patient groups, we were able to quantify the amount of
GS-Hb in terms of percentile values (see Materials and methods),
and these values were significantly higher in HD and CAPD
followedbyTxpwith respect to control group as shown inTable 2.
Table 1
Clinical and biochemical parameters of study subjects
Control (n=15) Transplant (n=15) CAPD (n=12) HD (n=15)
Age (years) 49±7.6 49.1±6.8 54.2±7.1 50.1±8.5
RRT duration (months) 47.2±32.3 24.9±12.1 28±17.3
Hemoglobin (g%) 14.27±1.51 13.10±1.49 10.93±1.76a 9.74±1.56a
Creatinine (mg/dL) 0.9±0.14 1.26±0.26 8.92±2.31 8.60±2.84
Cholesterol (mg/dL) 155.47±80.8 181.8±38.81a 181.4±36.01a 146.07±41.13ns
Triglycerides (mg/dL) 100.13±26.79 169±55.41c 170.27±60.85c 167.07±63.68b
HDL cholesterol (mg/dL) 44.93±7.50 42.93±11.0ns 38.2±8.94a 34.6±7.01b
LDL cholesterol (mg/dL) 90.50±19.36 104±18.40 109.15±30.29 78.05±41.27
Albumin (g/dL) 4.26±0.46 3.75±0.55 3.52±0.41 3.45±0.39
CRP (mg/L) 3.10±2.1 9.5±7.85a 15.74±12.1c 14.62±10.63c
HbA1c (%) 5.4±0.36 5.85±0.51 6.26±0.77c 5.62±0.67
Oxidative stress markers in erythrocytes
GSH (mmol/L) 2.26±0.31 2.50±0.55ns 1.72±0.49b 1.65±0.29c
TBARS (nmol/g Hb) 4.15±0.79 5.19±1.07a 8.11±1.99c 9.78±3.07c
Data are the mean±SD. n=no of subjects.
apb0.05, bpb0.01, cpb0.001 – compared to control group; ns – not significant.
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pb0.001) whereas lipid peroxidation and the GS-Hb levels
showed positive correlation (r=0.6, pb0.001). The average
glycated haemoglobin (Hbα and Hbβ) from ESI-MS showed
good correlation with the percent HbA1c from conventional
HPLC (r=0.53, pb0.05) (Table 2).Fig. 1. ESI mass spectrum of haemoglobin sample from a normal subject: (A) α gl
15,288 Da (inset). (B) β globin chain and its adducts with deconvoluted masses ofIn vitro glutathionylation of normal human haemoglobin
sample incubated with oxidized glutathione (GSSG) showed a
pronounced peak for 16,171 Da, corresponding to glutathiony-
lated beta chain (Fig. 4). Digestion of GS-Hb with chymo-
trypsin yielded a peptide fragment with mass of 2374 Da and a
peak of low intensity having a mass of 2069 Da. The peptide ofobin chain and its adduct with deconvoluted masses of α 15,125 Da, Gly-Hbα
β 15,866 Da, Gly-Hbβ 16,028 Da and GS-Hb 16,171 Da (inset).
Fig. 2. ESI mass spectrum of haemoglobin sample from patients belonging to different renal replacement therapy groups. Panels A, B and C show mass spectrum of α
globin chain and its adducts in a transplant, CAPD and HD patients with deconvoluted masses of α 15,125 Da and Gly-Hbα 15,287 Da (inset).
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in beta globin chain of haemoglobin, which contains a Cys
residue at position 93. The peptide of mass 2374 Da may be
attributed to glutathionylation (ΔM=305 Da) of Cys 93 residue
in 2069 Da fragment.
The tandem mass spectrum of the precursor peptide ion
having a mass of 2373.97 Da consists of a series of ‘b’ and ‘y’
ions (Fig. 5). Assignment of these molecular ions along with
their neutral losses, followed by de novo sequencing, confirms
that the peptide fragment corresponds to the residue 86–103 of
Hb β-chain. The resulting mass difference of 408 between b7
and b8 in ‘b’ ion series and y10 and y11 in ‘y’ ion series
confirms that Cys-93 of the beta globin chain is the site of
glutathione attachment via a disulfide bridge.
Discussion
S-Glutathionylated proteins have been investigated as possi-
ble biomarkers of oxidative stress in correlationwith disease. The
variations in glutathionylated proteins, caused by pathophysio-
logical conditions, can make them mediators of important
functions or parameters of clinical significance [23]. Though
earlier studies have indicated elevated levels of GS-Hb in uremicpatients [19], our study assumes importance as we have tried to
assess the utility of this marker in dialysis as well as transplant
patients in conjunction with other markers of oxidative stress.
Oxidative stress has long been implicated as one of the co-
morbid factors leading to premature mortality in relation to
dialysis [24,25]. Persistence of oxidative stress after successful
transplantation was reported by several authors [26–29]. Main-
tenance treatment with immunosuppressive drugs like cyclos-
porine (CsA) may enhance ROS production in transplant
patients [30,31]. Increased erythrocyte TBARS levels and de-
creased GSH levels in dialysis group compared to the transplant
group indicates an increased production of ROS and impairment
of the antioxidant defence system. This is supported by a
negative correlation between GSH and TBARS. The trend
observed with GS-Hb was similar to the above two parameters.
Significantly elevated GS-Hb levels in the dialysis group could
be due to oxidative perturbations arising out of substitutive
therapies. In case of HD patients, as mentioned earlier, it could
be due to repeated blood loss, contact with dialyzer membranes,
loss of vital soluble antioxidants like vitamin C during dialysis,
malnutrition, intravenous iron supplementation and inflamma-
tion (as evidenced by elevated CRP levels; Table 2) all of which
could be responsible for high oxidative stress.
Fig. 3. ESI mass spectrum of haemoglobin sample from patients belonging to different RRT groups. Panels A, B and C show mass spectrum of β globin chain and its
adducts in a transplant, CAPD and HD patients with deconvoluted masses of β 15,866 Da, Gly-Hbβ 16,028 Da and GS-Hb 16,171 Da (inset).
Table 2
Hb adducts Category
Control group
(n=15)
Transplant
group
(n=15)
Peritoneal
dialysis group
(n=12)
Hemodialysis
group (n=15)
GS-Hb (%) 3.15±1.99 4.69±3.19 7.63±1.81a 9.99±2.97a
Gly-Hbβ (%)
(ESI-MS)
5.08±0.89 7.65±3.78 7.77±1.37 6.92±2.27
Gly-Hbα (%)
(ESI-MS)
4.09±1.77 5.06±1.71 5.81±1.52 5.06±2.9
Average glycation
(%) (ESI-MS)
4.60±1.33 6.35±2.74 6.8±1.44a 5.99±2.58
HbA1c (%)
(HPLC)
5.2±0.35 6.12±0.96 6.3±0.49a 5.71±0.61
Glutathionylated Hb and glycated adducts of β and α subunits by ESI-MS and
HbA1c in control and renal replacement therapy group.
Values are mean±SD. n=number of subjects.
a pb0.05.
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inflammation of the peritoneum, malnutrition and hyperglycae-
mia from the dialysate solution could contribute to the oxidative
burden. Previous studies have indicated increased lipid perox-
idation and reduced GSH in erythrocytes and mesangial cells
subjected to hyperglycaemia [21,32]. The reduced GSH levels
are accompanied by decreased activity of gamma-glutamylcys-
teine synthetase, the rate-limiting enzyme in the de novo
synthesis of GSH as well as a reduced glucose-6-phosphate
dehydrogenase (G-6-PD) activity, which supplies NADPH for
glutathione reductase to reduce GSSG inside the erythrocytes, as
indicated by previous studies in uremic population [33–35].
Reduced levels of GSH in the dialysis group may represent an
imbalance of redox signalling, favouring increased formation of
GSSG and subsequent protein glutathionylation which is in
agreement with our findings. Hence, increased GSSG as a
consequence of decreased glutathione reductase activity and G-
6-PD activity could be responsible for increased erythrocyte
GSSG concentration, favouring GS-Hb formation.
In case of transplant subjects the intracellular GSH levels are
comparable to that of controls. These findings indicate thatoxidative stress may induce post-translational changes in
proteins, which might play an important role in the maintenance
and progression of disease. Protein glutathionylation promises to
Fig. 4. ESI mass spectrum of in vitro glutathionylated human haemoglobin with α, β and glutathionylated β globin chain with deconvoluted masses of α 15,125 Da, β
15,866 Da and an intense peak for GS-Hb 16,171 Da.
Fig. 5. Tandem mass spectra of precursor peptide 2373.97 Da. Series of ‘b’ and ‘y’ ions are labeled. De novo sequence of peptide is shown (inset).
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stressed conditions like uremia and associated complication
arising out of different RRT.
The utility of glutathionyl haemoglobin as a clinical marker
can only be judged if studies are extended to a much larger
group of chronic renal failure patients. In the design of our
study, we have deliberately excluded diabetic patients from our
sample because increased glutathionyl haemoglobin level has
been previously reported in the case of diabetes. Restrictions
imposed by limiting the study to a non-diabetic patient group
limit the number of subjects who can be recruited into such a
study. It would therefore be premature to suggest that
glutathionyl haemoglobin can be used in clinical evaluation in
the case of chronic renal failure patients who are under specific
treatment regimens.
The average levels of glycated haemoglobin measured by
mass spectrometry showed good correlation with HbA1c
determined by HPLC across the RRT groups with a slight
decrement in the control group. Quantitation of glycated species
served to substantiate the fact that GS-Hb quantitation by mass
spectrometry is reliable. Extensions to other haemoglobin
adduct characterization and quantitation merits further study.
Human adult haemoglobin is a tetramer molecule (α2β2) with
one Cys residue in the alpha chain and two in the beta chain.
Efficient in vitro glutathionylation of haemoglobin establishes
the fact that Cys-93 of beta globin chain is the preferred site for
non-enzymatic attachment of glutathione leading to the forma-
tion of GS-Hb, which is in agreement with the surface
accessibility of beta Csy-93 residue from previous studies
[36,37].
In conclusion, intracellular GSH redox balance is a key
factor that determines the protein functionality with respect to
oxidative stress. Glutathionylated proteins like GS-Hb can serve
as good clinical markers of oxidative stress in chronic
debilitating substitutive therapies like dialysis and transplanta-
tion. Whether GS-Hb merely serves as an indicator or is
associated with the pathogenesis of RRT associated complica-
tions needs to be evaluated.
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